How to Help Your Patients Find Dapagliflozin in Stock: A Provider's Guide

Helping Your Patients Maintain Access to Dapagliflozin

When you prescribe Dapagliflozin (Farxiga) for a patient with heart failure, chronic kidney disease, or type 2 diabetes, you expect them to be able to fill it. But patients are increasingly reporting that their pharmacy doesn't have it in stock — or that cost barriers prevent them from picking it up.

As a provider, you're uniquely positioned to help patients navigate these challenges. This guide outlines practical steps your care team can take to ensure continuity of therapy with Dapagliflozin.

Current Availability of Dapagliflozin

As of early 2026, Dapagliflozin is not in a formal FDA-declared shortage. However, pharmacy-level stock-outs occur intermittently due to:

• Surging demand across cardiology, nephrology, endocrinology, and primary care
• Generic manufacturers still scaling production after the 2025 launch
• Chain pharmacy inventory models that may not anticipate spikes in new prescriptions
• Formulary changes and prior authorization requirements that create fill delays

The result is that patients may visit 2–3 pharmacies before finding Dapagliflozin in stock, or they may abandon the prescription entirely — leading to treatment gaps.

Why Patients Can't Find Dapagliflozin

Understanding the patient experience helps you intervene effectively:

Chain Pharmacies and Inventory Limits

Large chain pharmacies use automated ordering systems based on historical demand. If a pharmacy hasn't filled many Dapagliflozin prescriptions recently, it may not stock it regularly. Patients who are new to the medication — or who have recently switched pharmacies — are especially likely to encounter this.

Brand vs. Generic Confusion

Some pharmacies stock brand-name Farxiga but not generic Dapagliflozin, or vice versa. Patients (and some pharmacy staff) may not realize that both versions are available and interchangeable, leading to unnecessary "out of stock" messages.

Insurance Barriers

Prior authorization requirements, step therapy mandates (often requiring prior Metformin use for the diabetes indication), and formulary tier placement all affect whether and where a patient can fill their prescription. These delays can cause patients to go days or weeks without medication.

Cost Shock

Patients who arrive at the pharmacy and face a $550–$650 cash price for brand-name Farxiga (or $288–$405 for the generic) may simply walk away. This is particularly common for patients who haven't been connected to savings programs.

What Providers Can Do: 5 Actionable Steps

Step 1: Check Availability Before the Patient Leaves Your Office

Use Medfinder for Providers to check real-time pharmacy stock in the patient's area. By identifying a pharmacy that has Dapagliflozin available before sending the prescription, you significantly reduce the chance of a failed fill.

This takes less than a minute and can be delegated to nursing staff, medical assistants, or care coordinators.

Step 2: Specify Generic Acceptable on All Prescriptions

Unless there is a documented medical necessity for brand-name Farxiga, always indicate that generic substitution is acceptable. This gives the pharmacy maximum flexibility to fill from whatever stock they have available.

Generic Dapagliflozin is available in both 5 mg and 10 mg tablets from multiple manufacturers and is therapeutically equivalent to Farxiga.

Step 3: Proactively Initiate Prior Authorization

For patients whose insurance requires prior authorization, initiate the PA process at the time of prescribing — not after the pharmacy requests it. Include:

• The specific FDA-approved indication (type 2 diabetes, heart failure, or CKD)
• Relevant clinical data (HbA1c, eGFR, LVEF, NYHA class)
• Documentation of prior therapies if step therapy is required
• A letter of medical necessity if the patient needs brand-name specifically

This proactive approach can shave days off the fill timeline.

Step 4: Connect Patients with Cost Resources

At the point of prescribing, share relevant savings programs with the patient:

• AstraZeneca Farxiga Savings Card: Eligible commercially insured patients may pay as low as $0/fill (max savings $175/fill)
• AZ&Me Patient Assistance Program: Free medication for qualifying uninsured/underinsured patients
• Discount coupons: GoodRx and SingleCare can reduce generic Dapagliflozin costs to approximately $288–$405/month
• Prescription Hope: Offers Dapagliflozin for $70/month for eligible patients

For comprehensive savings guidance, direct patients to our article on saving money on Dapagliflozin.

Step 5: Have a Backup Plan Ready

When Dapagliflozin is truly unavailable, be prepared to discuss alternatives:

• Empagliflozin (Jardiance): The closest therapeutic alternative, with overlapping indications for diabetes, heart failure, and CKD
• Canagliflozin (Invokana): Effective for diabetes and diabetic nephropathy, though it carries an amputation risk warning
• Ertugliflozin (Steglatro): Diabetes-only indication; not suitable for heart failure or CKD patients

For more on therapeutic alternatives, see our article on alternatives to Dapagliflozin.

Workflow Tips for Your Care Team

Integrating these steps into your clinical workflow doesn't have to be burdensome:

• Create a standing order set or smart phrase in your EHR that includes the PA justification language for Dapagliflozin across all three indications
• Train front-desk and MA staff to check Medfinder for Providers when processing Dapagliflozin prescriptions
• Build a patient handout with links to savings programs and pharmacy-finding tools
• Use after-visit summaries to include information about the AstraZeneca Savings Card and generic options
• Set follow-up reminders to check whether new patients on Dapagliflozin were able to fill their prescription within the first week

Alternative SGLT2 Inhibitors: Quick Comparison

When switching is necessary, here's a quick reference:

• Empagliflozin (Jardiance): 10 mg or 25 mg daily. Approved for T2DM, HF, CKD. Closest overall substitute.
• Canagliflozin (Invokana): 100 mg or 300 mg daily. Approved for T2DM, CV risk reduction, diabetic nephropathy. Note amputation risk.
• Ertugliflozin (Steglatro): 5 mg or 15 mg daily. T2DM only. Adults only.
• Bexagliflozin (Brenzavvy): 20 mg daily. T2DM only. Limited outcomes data.

For a more detailed comparison, see our provider shortage briefing.

Final Thoughts

Dapagliflozin is an essential therapy for millions of patients, and ensuring access requires more than just writing a prescription. By checking availability proactively, streamlining prior authorizations, connecting patients with cost resources, and having alternatives ready, your practice can prevent treatment gaps and improve patient outcomes.

Bookmark Medfinder for Providers as a go-to resource, and share patient-facing guides like how to find Dapagliflozin in stock and what patients should know about Dapagliflozin.